Published in Proc Natl Acad Sci U S A on April 03, 2006
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
CD56bright natural killer (NK) cells: an important NK cell subset. Immunology (2009) 2.25
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med (2012) 2.14
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol (2010) 1.57
Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. Am J Respir Crit Care Med (2013) 1.50
Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci (2016) 1.48
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
Adaptive immune responses mediated by natural killer cells. Immunol Rev (2010) 1.48
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol (2007) 1.45
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci (2007) 1.39
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
Daclizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 1.33
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol (2007) 1.29
Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods (2008) 1.28
Natural killer cells in human autoimmune diseases. Immunology (2010) 1.27
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol (2011) 1.18
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther (2007) 1.13
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol (2013) 1.13
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
The innate immune system in demyelinating disease. Immunol Rev (2012) 1.10
Natural killer cells in human autoimmune disorders. Arthritis Res Ther (2013) 1.10
Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2. Proc Natl Acad Sci U S A (2010) 1.09
Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One (2012) 1.09
Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med (2009) 1.09
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One (2012) 1.08
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol (2007) 1.05
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J Clin Cell Immunol (2013) 1.04
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation (2008) 0.99
Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology (2008) 0.98
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.96
Natural killer cells: role in local tumor growth and metastasis. Biologics (2012) 0.94
Subsets of human natural killer cells and their regulatory effects. Immunology (2014) 0.93
The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int (2014) 0.93
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood (2008) 0.93
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm (2015) 0.92
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol (2014) 0.92
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A (2016) 0.92
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol (2013) 0.91
Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem Biophys Res Commun (2007) 0.91
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2014) 0.89
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. PLoS Med (2016) 0.89
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. PLoS One (2012) 0.89
IL-27 imparts immunoregulatory function to human NK cell subsets. PLoS One (2011) 0.88
Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord (2013) 0.87
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One (2012) 0.86
Natural killer cells as indispensable players and therapeutic targets in autoimmunity. Autoimmunity (2010) 0.86
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology (2014) 0.86
Identification of human NK17/NK1 cells. PLoS One (2011) 0.86
T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy (2010) 0.86
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs (2010) 0.86
Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development. PLoS One (2012) 0.85
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2009) 0.85
Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs (2009) 0.85
Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Res Ther (2013) 0.85
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol (2013) 0.84
Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes (2013) 0.84
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol (2014) 0.84
Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol (2015) 0.83
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology (2016) 0.83
Cysteine cathepsins as regulators of the cytotoxicity of NK and T cells. Front Immunol (2014) 0.83
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis. Mult Scler (2013) 0.83
Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet (2010) 0.83
Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J Neuroinflammation (2014) 0.83
Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. J Autoimmun (2011) 0.83
Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem (2014) 0.82
Boosting vaccine efficacy the natural (killer) way. Trends Immunol (2015) 0.82
A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One (2014) 0.82
Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. Eur J Hum Genet (2011) 0.81
Emerging immunopharmacological targets in multiple sclerosis. J Neurol Sci (2015) 0.81
CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology (2013) 0.81
Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis. Int Immunol (2011) 0.81
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics (2016) 0.81
Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia. PLoS One (2013) 0.81
How implementation of systems biology into clinical trials accelerates understanding of diseases. Front Neurol (2014) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Innovative monoclonal antibody therapies in multiple sclerosis. Ther Adv Neurol Disord (2008) 0.80
Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1). J Neuroinflammation (2012) 0.80
Personalized medicine in multiple sclerosis: hope or reality? BMC Med (2012) 0.80
T-bet-dependent NKp46(+) innate lymphoid cells regulate the onset of TH17-induced neuroinflammation. Nat Immunol (2017) 0.79
Determination of lymphocyte division by flow cytometry. J Immunol Methods (1994) 11.48
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
T cell fitness determined by signal strength. Nat Immunol (2003) 3.65
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med (1997) 2.17
The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol (2000) 2.17
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A (1999) 2.14
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2004) 1.73
Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol (2003) 1.72
A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum (2002) 1.71
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol (2003) 1.60
Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol (1998) 1.56
The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol (1998) 1.33
The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol (2002) 1.30
Natural killer cells and autoimmunity. Arthritis Res Ther (2003) 1.14
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc (1998) 1.10
Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua. Int Immunol (1991) 1.09
Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol (1998) 1.08
Control of autoimmunity by regulatory T cells. Adv Exp Med Biol (2001) 1.07
Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol (1999) 0.98
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol (2000) 0.98
Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol (2000) 0.96
Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. Proc Natl Acad Sci U S A (1994) 0.96
DA rat NK(+)CD3(-) cells inhibit autoreactive T-cell responses. J Neuroimmunol (2001) 0.89
Multiple Sclerosis: Immunotherapy. Curr Treat Options Neurol (1999) 0.85
Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab. Transplant Proc (2001) 0.85
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 6.10
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A (2003) 2.20
Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol (2010) 2.19
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A (2004) 1.92
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood (2011) 1.86
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol (2008) 1.85
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A (2007) 1.76
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain (2003) 1.75
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A (2008) 1.72
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U S A (2002) 1.69
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A (2012) 1.64
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2004) 1.62
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
ITK and IL-15 support two distinct subsets of CD8+ T cells. Proc Natl Acad Sci U S A (2006) 1.55
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med (2002) 1.48
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res (2003) 1.43
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood (2010) 1.41
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A (2006) 1.39
Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci U S A (2005) 1.37
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood (2006) 1.33
Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity (2004) 1.30
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A (2009) 1.28
Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A (2010) 1.27
Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8(+) T-cell response. Blood (2006) 1.26
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res (2002) 1.25
Perforin and the granule exocytosis cytotoxicity pathway. Curr Opin Immunol (2003) 1.25
IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. Proc Natl Acad Sci U S A (2004) 1.25
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. J Immunol (2007) 1.24
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18
Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med (2003) 1.18
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
IL-15 is a growth factor and an activator of CD8 memory T cells. Ann N Y Acad Sci (2002) 1.15
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol (2004) 1.15
Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood (2003) 1.14
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res (2003) 1.11
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A (2009) 1.11
The value of animal models for drug development in multiple sclerosis. Brain (2006) 1.11
Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res (2004) 1.09
Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood (2009) 1.09
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res (2010) 1.07
Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood (2008) 1.07
Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol (2004) 1.07